ClinicalTrials.gg
CompletedNCT06657560Updated Jul 18, 2025

Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function

A Phase 1 interventional study of HRS-9231 in Contrast-Enhanced Magnetic Resonance Imaging Detection, sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-18.

Sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is an open-label, non-randomized, parallel cohorts design, multicenter, single dose phase I study.

The primary objectives are:

To evaluate the pharmacokinetics (plasma and urine) profile of HRS-9231 following single intravenous injection (0.05 mmol/kg body weight) in patients with mild to severe renal impairment and in healthy volunteers with normal renal function used as reference.

To assess dialysability of HRS-923 following a single intravenous injection (0.05 mmol/kg body weight) in patients with end stage renal disease requiring hemodialysis.

02

Conditions studied

  • Contrast-Enhanced Magnetic Resonance Imaging Detection
03

In context

Lead sponsor

Shanghai Shengdi Pharmaceutical Co., Ltd is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, ages 18 to 65, inclusive, at the time of .
  2. Female subjects weigh ≥ 45 kg, male subjects weigh ≥ 50 kg, and between 18.0 and 28.0 kg/m2, inclusive, at screening.
  3. Have an expressed in mL/min/1.73m2 (MDRD formula estimation) at screening within the range of:

    Cohort A - normal renal function: ≥ 90 mL/min and \< 130 mL/min; Cohort B - mild renal impairment: 60 \< 90 mL/min; Cohort C - moderate renal impairment: 30 \< 60 mL/min; Cohort D - severe renal impairment: 15 \< 30 mL/min; Cohort E - ESRD subjects requiring HD: \< 15 mL/min.

  4. The renal function is required to be stable. The interval between two assessments during the screening period should be at least 72 hours apart (the first renal function assessment result may use historical values with 30 days before screening), and the two assessments should be consistent with the same renal function classification and two values have to show ≤25%. If the two assessments are inconsistent in terms of renal function category, the third assessment has to be conducted at least 72 hours after the second assessment. If the second and third assessments differ, the subject will be ineligible for the study.

Exclusion criteria

Exclusion Criteria:

  1. Subject with any history of severe allergic or anaphylactic reactions to any allergen including drugs and contrast agents, or allergic disease diagnosed and treated by a physician.
  2. Subject has positive results at screening for (HIV), surface antigen (HBsAg), virus (HCV), or treponema pallidum antibody.
  3. Subjects who have undergone major surgery within 3 months before screening, or those who have received surgery that may significantly affect the pharmacokinetics or safety evaluation of the study drug, are judged by the investigators to be unsuitable for participation.
  4. Participated in other clinical trials within 3 months before screening or plan to participate in other clinical trials during this study.
  5. Blood loss or blood donation of more than 200 mL within 3 months before screening, or intended to donate blood during or within 1 month after the end of the trial.
  6. Those who have been vaccinated with inactivated/live/attenuated vaccines within 1 month before screening or who have an intention to vaccinate during the trial.
  7. History of kidney transplantation surgery.
  8. Patients with mild, moderate, or severe renal impairment are expected to receive any type of dialysis during the study (cohort B-D); Those who need treatment other than intermittent hemodialysis therapy during the study period, or those who have not been able to maintain a stable hemodialysis of 2 to 4 times per week for at least 1 month before administration (Group E).
  9. Incontinence or anuria (e.g., \<100 mL/d) in patients with mild, moderate, and severe renal impairment (B-D group).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Cohort A

    Healthy volunteer with stable normal renal function defined with an absolute value of eGFR ≥ 90 and \< 130 mL/min based on two eGFR assessments done at screening and inclusion, with a maximum tolerance of 25% between the 2 measurements.

    Drug: HRS-9231

  • Experimental
    Cohort B

    Patient with stable mild renal impairment defined with an absolute value of eGFR ≥ 60 and \<90 mL/min included based on two eGFR assessments done at screening and inclusion, with a maximum tolerance of 25% between the 2 measurements.

    Drug: HRS-9231

  • Experimental
    Cohort C

    Patient with stable moderate renal impairment defined with an absolute value of eGFR between ≥ 30 and \<60 mL/min included based on two eGFR assessments done at screening and inclusion, with a maximum tolerance of 15% between the 2 measurements.

    Drug: HRS-9231

  • Experimental
    Cohort D

    Patient with stable severe renal impairment defined with an absolute value of eGFR between ≥ 15 and \<30 mL/min included based on two eGFR assessments done at screening and inclusion, with a maximum tolerance of 15% between the 2 measurements.

    Drug: HRS-9231

  • Experimental
    Cohort E

    Patient with end-stage renal failure who requires 3 hemodialysis sessions per week and defined with an absolute value of eGFR \<15 mL/min.

    Drug: HRS-9231

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Observed maximum plasma concentration. Blood samples will be collected.

    Time frame: Prior to HRS-9231 administration and Day 5 (for all cohorts) or Day 6 (only for cohort D).

  2. AUC0-t

    Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration. Blood samples will be collected.

    Time frame: Prior to HRS-9231 administration and Day 5 (for all cohorts) or Day 6 (only for cohort D).

  3. AUC0-∞

    Area under the plasma concentration-time curve from time 0 to infinity. Blood samples will be collected.

    Time frame: Prior to HRS-9231 administration and Day 5 (for all cohorts) or Day 6 (only for cohort D).

  4. Tmax

    Observed time to reach C(max). Blood samples will be collected.

    Time frame: Prior to HRS-9231 administration and Day 5 (for all cohorts) or Day 6 (only for cohort D).

  5. Ae

    Amount excreted. Urine samples will be collected.

    Time frame: Prior to HRS-9231 administration and Day 5 (for all cohorts) or within 6 days (only for cohort D) after administration.

Secondary outcomes

  1. Incidence of treatment emergent AEs (TEAEs)

    Time frame: From screening visit to 6 months after administration.

07

Study locations

1 site
  • Shandong First Medical University First Affiliated Hospital (Shandong Qianfoshan Hospital)
    Jinan, Shandong 250014, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Jul 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Oct 24, 2024
StartActual
Oct 14, 2024
Primary completionActual
Jul 3, 2025
CompletionActual
Jul 3, 2025
Last update
Jul 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06657560
Responsible party
Sponsor
First posted
Oct 24, 2024
Start date
Oct 14, 2024
Primary completion
Jul 3, 2025
Completion
Jul 3, 2025
Last update
Jul 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9231

Start the discussion